The company said in a post on LinkedIn that doctors at the Ottawa Heart Institute completed the first commercial case with Varipulse. Johnson & Johnson said the procedure “marks a significant step forward” in the treatment of AFib with the pulsed field ablation (PFA) technology.
“A huge thank you to the Ottawa Heart Institute for their partnership in bringing this groundbreaking treatment to Canada,” the company wrote. “Together, we’re committed to advancing cardiac arrhythmia management and helping those with this condition live the lives they want.”
The Varipulse system features the Varipulse catheter, a variable-loop multielectrode catheter. The platform also includes TruPulse generator and the Carto 3 3D cardiac mapping system. Carto integration enables an intuitive and reproducible workflow with real-time visualization and feedback mechanisms.
J&J MedTech designed Varipulse to enable pulmonary vein isolation with the versatility of a catheter loop, simple generator user interface and an intuitive mapping system. It also features contact indicators and PF tagging mechanisms.
Johnson & Johnson MedTech submitted Varipulse for FDA approval at the end of March. If approved, Varipulse would become the third PFA system FDA-authorized for treating AFib, following Medtronic and Boston Scientific.
